Kent Meredith, MD
Interventional Cardiology · Salt Lake City, UTNPI 1598966822
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.7% of the total across 7 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 4 manufacturers reported payments, led by Shockwave Medical, Inc at 30.6% of the total. 2025 is the largest year on record at $366, 2.1 times the $176 reported in 2022. That places this record below the midpoint for interventional cardiology clinicians in UT, where the typical reported total is $5,946.
Across 7 payments — averaging $104.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Shockwave Medical, Inc$223
- Abbott$185
- Heartflow, Inc.$176
- Boston Scientific$143
Across 15 payments — averaging $13,239 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$199K
What the payments were for
- Consulting fees$324%
- Food & beverage$69796%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Shockwave Medical, Inc | 1 | $223 |
| Abbott | 1 | $185 |
| Heartflow, Inc. | 2 | $176 |
| Boston Scientific | 3 | $143 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$728 in reported general payments places this provider in the 10th percentile of 45 interventional cardiology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 48 | $67,391 |
| EliquisApixaban | 42 | $62,408 |
| Repatha SureclickEvolocumab | 27 | $29,701 |
| Atorvastatin Calcium | 326 | $4,670 |
| Carvedilol | 158 | $2,572 |
| ClopidogrelClopidogrel Bisulfate | 156 | $2,385 |
| Rosuvastatin Calcium | 128 | $1,950 |
| Metoprolol Succinate | 123 | $1,829 |
| Losartan Potassium | 135 | $1,812 |
| Isosorbide Dinitrate | 14 | $1,608 |
| Lisinopril | 176 | $1,461 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 90 | $1,294 |
| Potassium Chloride | 51 | $1,067 |
| Metoprolol Tartrate | 118 | $983 |
| Valsartan | 34 | $928 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Salt Lake City
- Vamsee YagantiSalt Lake City$390K
- Anwar TandarSalt Lake City$131K
- Stavros DrakosSalt Lake City$79K
- Frederick WeltSalt Lake City$26K
- Scott HackingSalt Lake City$22K
- Eric LindleySalt Lake City$18K
- Lee LinstrothSalt Lake City$14K
- Theophilus OwanSalt Lake City$9K
- Diana MeloSalt Lake City$4K
- Tara JonesSalt Lake City$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.